Sacituzumab govitecan
Phase 2Recruiting 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Differentiated Thyroid Cancer
Conditions
Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer
Trial Timeline
Sep 13, 2024 → Dec 1, 2027
NCT ID
NCT06235216About Sacituzumab govitecan
Sacituzumab govitecan is a phase 2 stage product being developed by Gilead Sciences for Differentiated Thyroid Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06235216. Target conditions include Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06923826 | Phase 2 | Recruiting |
| NCT06665178 | Phase 2 | Recruiting |
| NCT06235216 | Phase 2 | Recruiting |
| NCT06329869 | Phase 2 | Recruiting |
| NCT06263543 | Phase 2 | Recruiting |
| NCT06123468 | Phase 1/2 | Completed |
| NCT05833867 | Phase 1 | Recruiting |
| NCT06028932 | Phase 2 | Active |
| NCT05552001 | Phase 3 | Recruiting |
| NCT05884320 | Phase 2 | Recruiting |
| NCT05581589 | Phase 2 | Recruiting |
| NCT05838521 | Phase 2 | Recruiting |
| NCT04647916 | Phase 2 | Active |
| NCT04251416 | Phase 2 | Active |
| NCT03995706 | Phase 1 | Completed |
| NCT03725761 | Phase 2 | Active |
Competing Products
20 competing products in Differentiated Thyroid Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CAB-AXL-ADC + PD-1 inhibitor | BioAtla | Phase 1/2 | 33 |
| Abemaciclib + Placebo | Eli Lilly | Phase 3 | 77 |
| Lenvatinib + Placebo | Eisai | Phase 3 | 77 |
| Lenvatinib | Eisai | Pre-clinical | 23 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| LENVATINIB | Eisai | Phase 2 | 52 |
| Selpercatinib Monotherapy | Eli Lilly | Phase 2 | 52 |
| Selumetinib + Placebo + Radioactive Iodine Therapy | AstraZeneca | Phase 3 | 77 |
| Pembrolizumab + Cisplatin + Docetaxel + Carboplatin | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| sunitinib + everolimus + chemotherapies recommended in france | Novartis | Pre-clinical | 23 |
| Everolimus + Sorafenib | Novartis | Phase 2 | 52 |
| Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placebo | Novartis | Phase 3 | 77 |
| PDR001 | Novartis | Phase 2 | 52 |
| Everolimus (Afinitor®) | Novartis | Phase 2 | 52 |
| sunitinib | Pfizer | Approved | 84 |
| Vandetanib (SAR390530) + Placebo | Sanofi | Phase 3 | 76 |
| Thyrogen (thyrotropin alfa for injection) | Sanofi | Phase 3 | 76 |
| Cabazitaxel | Sanofi | Phase 2 | 51 |
| Larotrectinib monotherapy | Bayer | Phase 2 | 49 |